About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
R
Experts Discuss How They Choose 2L Therapy in MF
By
MyCancerHaven
FEATURING
Ravi Vij
,
Prithviraj Bose
By
MyCancerHaven
FEATURING
Ravi Vij
,
Prithviraj Bose
126 views
August 30, 2024
0 Comments
Login to view comments.
Click here to Login
Featured Video
15:43
Incyte
Importance of Early Management of Patients with Myelofibrosis (MF)
Feat.
P. Bose,
R. Rampal
Featured Video
16:51
Incyte
Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk
Feat.
C. Harrison
Related Content
AUTOPLAY
ON
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
18:04
Ruben Mesa
Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…
27:37
Indy Hematology Review
Review of Myeloproliferative Neoplasms
Feat.
A. Tefferi
14:01
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in Heme Malignancies
Feat.
M. Gomes da Silva
06:18
Cleveland Clinic Taussig Cancer Institute
SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…
Feat.
A. Gerds
16:26
Incyte
Effects of a Treatment Option on Hematocrit Control and Spleen Volum…
Feat.
C. Harrison
24:48
Indy Hematology Review
2024 Updates on Myelofibrosis and Systemic Mastocytosis
Feat.
R. Rampal
21:52
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…
Feat.
D. Tremblay
10:02
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…
Feat.
R. Mesa
18:42
Memorial Sloan Kettering Cancer Center
Key Updates in AML, MDS, & MF From ASH
Feat.
A. Goldberg
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
11:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
2024 Updates in Myeloproliferative Neoplasms
Feat.
E. Hexner
08:11
Krisstina Gowin
Counseling Patients With Newly Diagnosed PV or ET
31:43
Indy Hematology Review
Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…
Feat.
A. Tefferi
17:23
Vanderbilt University Medical Center (VUMC)
Management of MF After Ruxolitinib Failure
Feat.
A. Kishtagari
11:03
Moffitt Cancer Center
Current Treatment Landscape of JAK Inhibitors in MF
Feat.
A. Kuykendall
09:27
ASH 2022 Conference Coverage
MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…
Feat.
M. McMullin
12:18
Fred Hutchinson Cancer Center
Management of MPNs for the Community Oncologist
Feat.
H. Deeg
13:38
Insights from 2024 EHA Annual Meeting
Top 5 Impactful MPN Abstracts From Summer Conferences
Feat.
P. Bose
